Last updated on June 2017

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD or Pembrolizumab in Adults With FRa + Adv. EOC Primary Peritoneal Fallopian Tube or Endometrial Cancer


Brief description of study

This is a phase 1b study to assess the safety, tolerability, and preliminary anti-tumor activity of IMGN853 when administered with chemotherapy. Patients will be assigned to one of four regimens: IMGN853 administered with bevacizumab, IMGN853 administered with carboplatin, IMGN853 administered with pegylated liposomal doxorubicin or IMGN853 administered with pembrolizumab.

Detailed Study Description

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Clinical Study Identifier: NCT02606305

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

ImmunoGen Clinical Operations

Massachusetts General Hospital
Boston, MA United States
  Connect »

ImmunoGen Clinical Operations

Dana-Farber Cancer Institute
Boston, MA United States
  Connect »

ImmunoGen Clinical Operations

The Ohio State University
Hilliard, OH United States
  Connect »

ImmunoGen Clinical Operations

Peggy and Charles Stephenson Oklahoma Cancer Center
Oklahoma City, OK United States
  Connect »

ImmunoGen Clinical Operations

Fox Chase Cancer Center
Philadelphia, PA United States
  Connect »

ImmunoGen Clinical Operations

Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut
Leuven, Belgium
  Connect »

ImmunoGen Clinical Operations

McGill University
Montreal, Canada
  Connect »